Radiotherapy for hormone-sensitive prostate cancer with synchronous low burden of distant metastases.
Arndt-Christian MüllerDaniel M AebersoldClemens AlbrechtDirk BöhmerMichael FlentjeUte GanswindtPirus GhadjarNina-Sophie Schmidt-HegemannStefan HöchtTobias HölscherPeter NiehoffMichael PinkawaFelix SedlmayerFrank WolfConstantinos ZamboglouDaniel ZipsThomas Wiegelnull nullPublished in: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2022)
Therefore, due to the survival benefit after 3 years, current practice is changing. New palliative SOC is radiotherapy of the primary tumor in synchronously metastasized prostate cancer with low metastatic burden (defined as ≤ 4 bone metastases, with or without distant nodes) or in case of distant nodes only detected by conventional imaging.